Cambridge Trust’s Editas Medicine EDIT Stock Holding History

Cambridge Trust’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,000	Closed	-$8.23K	–	721
2023 Q2	$8.23K	Hold	1,000	–	–	﹤0.01%	612
2023 Q1	$7.25K	Hold	1,000	–	–	﹤0.01%	653
2022 Q4	$9K	Hold	1,000	–	–	﹤0.01%	641
2022 Q3	$12K	Hold	1,000	–	–	﹤0.01%	623
2022 Q2	$12K	Hold	1,000	–	–	﹤0.01%	663
2022 Q1	$19K	Hold	1,000	–	–	﹤0.01%	668
2021 Q4	$27K	Buy	+1,000	New	+$34.4K	﹤0.01%	636

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cambridge Trust's EDIT Position: Q3 2023 in Review

Cambridge Trust sold out of Editas Medicine (EDIT) in Q3 2023, closing a stake of 1,000 shares — an estimated $8.23K sold.

Cambridge Trust first reported a position in EDIT in Q4 2021 and held it in 7 quarters. The position peaked at $27K in Q4 2021. 220 funds tracked by Wall St. Rank hold EDIT as of Q3 2023.

Cambridge Trust reported no remaining Editas Medicine position as of Q3 2023 after selling out during the quarter.
Cambridge Trust sold 1,000 Editas Medicine shares in Q3 2023, an estimated $8.23K.
Cambridge Trust first reported a position in Editas Medicine in Q4 2021 and held it in 7 quarters.
Cambridge Trust's Editas Medicine position peaked at $27K in Q4 2021.
220 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2023.

Based on Cambridge Trust's 13F filing for Q3 2023, filed 26 Oct 2023.